Tests abdominal pressure and ultrasound to guide water pill dosing in heart failure
Tests guiding water pill doses by abdominal pressure in adults with acute heart failure.
Plain-language title generated from the registry record
Registry title: The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure
Key facts
- Where
- Zaragoza, SpainSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07008365, who can take part
Where in Spain
- Hospital Clinico Universitario Lozano BlesaZaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto de Investigación Sanitaria Aragón
- Trial code
- NCT07008365
- Record updated
- 6 June 2025
- Original description
Systemic venous congestion is the primary therapeutic target of intravenous loop diuretics in patients admitted for acute heart failure (AHF). Despite their utility, a significant proportion of AHF patients are discharged with persistent clinical symptoms of congestion (residual congestion). Therefore, in recent years, there has been a growing focus on the use of tools (biomarkers, clinical ultrasound) that allow us to optimize diuretic treatment and thereby improve the prognosis of AHF patients. The objective is to analyze whether the strategy of guiding intravenous loop diuretic dosing based on intra-abdominal pressure(IAP) measurements and clinical ultrasound is superior to the conventional strategy employed in daily clinical practice. This study is a randomized, multicenter clinical trial involving consecutive patients admitted with a diagnosis of AHF in the Internal Medicine and Cardiology departments. Patients who meet the inclusion criteria, after signing informed consent, will be randomized into two groups: 1) Diuretic treatment guided by usual clinical practice and 2) Treatment guided by intra-abdominal pressure levels and clinical ultrasound (inferior vena cava and portal Doppler). This strategy will be maintained during the first 72 hours of admission, with a thorough analysis of congestion and diuretic response being conducted.Read full original descriptionShow less
The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure
Systemic venous congestion is the primary therapeutic target of intravenous loop diuretics in patients admitted for acute heart failure (AHF). Despite their utility, a significant proportion of AHF patients are discharged with persistent clinical symptoms of congestion (residual congestion). Therefore, in recent years, there has been a growing focus on the use of tools (biomarkers, clinical ultrasound) that allow us to optimize diuretic treatment and thereby improve the prognosis of AHF patients. The objective is to analyze whether the strategy of guiding intravenous loop diuretic dosing based on intra-abdominal pressure(IAP) measurements and clinical ultrasound is superior to the conventional strategy employed in daily clinical practice. This study is a randomized, multicenter clinical trial involving consecutive patients admitted with a diagnosis of AHF in the Internal Medicine and Cardiology departments. Patients who meet the inclusion criteria, after signing informed consent, will be randomized into two groups: 1) Diuretic treatment guided by usual clinical practice and 2) Treatment guided by intra-abdominal pressure levels and clinical ultrasound (inferior vena cava and portal Doppler). This strategy will be maintained during the first 72 hours of admission, with a thorough analysis of congestion and diuretic response being conducted.
Inclusion: Men or women over 18 years of age; Diagnosis of heart failure (HF) based on the latest HF guidelines published in 2022; N-terminal pro b-type natriuretic peptide (NT-proBNP) \> 1000 pg/mL or Brain Natriuretic Peptide (BNP) \> 250 pg/mL; Placement of a urinary catheter to allow for the measurement of intra-abdominal pressure; Intravascular or mixed congestion pattern, defined as the presence of one or more clinical signs of congestion (edema, ascites, and/or pleural effusion); Signed informed consent.
Exclusion: Patients receiving renal replacement therapy (ultrafiltration or peritoneal dialysis); Kidney transplant recipients; Heart rate at admission \> 170 beats per minute (bpm); Acute myocardial ischemia; History of hypersensitivity to hydrochlorothiazide or furosemide; Patients with recent cardiac surgery (within the last year) or heart transplant recipients; Need for inotropic support to maintain adequate cardiac and/or renal output; Serum hemoglobin \< 9 g/dL; Patient with a stay in the Internal Medicine department \> 24 hours; Absence of sufficient clinical congestion (ADVOR score = 0 at the time of randomization); Patient\'s refusal to participate in the clinical trial; Inability or contraindication for urinary catheter placement; Systolic blood pressure at admission \< 100 mmHg; Cardiogenic shock; Pregnancy or breastfeeding; Patients admitted from the Intensive Care Unit.